Verve Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
VERV Nasdaq 8731 https://www.vervetx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Verve Therapeutics Inc

Verve Therapeutics to Participate in the 2023 Jefferies Healthcare Conference - Jun 1st, 2023 10:30 am
Verve Therapeutics to Participate in the Stifel 2023 Tailoring Genes: Virtual Genetic Medicines Day - May 23rd, 2023 10:30 am
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates - May 15th, 2023 11:45 am
Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results - May 15th, 2023 10:30 am
We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate - May 11th, 2023 11:21 am
Verve Therapeutics to Participate in the RBC Capital Markets 2023 Global Healthcare Conference - May 9th, 2023 10:30 am
Top 10 CRISPR Stocks To Buy - Apr 20th, 2023 10:24 pm
Verve Therapeutics, Inc. (NASDAQ:VERV) insider upped their holding by 2.4% earlier this year - Mar 31st, 2023 4:04 pm
Verve Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day - Mar 27th, 2023 10:30 am
Verve Therapeutics (NASDAQ:VERV) shareholders are up 4.6% this past week, but still in the red over the last year - Mar 4th, 2023 12:32 pm
Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates - Mar 3rd, 2023 11:30 am
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results - Mar 2nd, 2023 11:30 am
3 Deeply Undervalued Stocks That Could Double Your Money - Feb 15th, 2023 2:00 pm
Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by the UK MHRA for the Treatment of Heterozygous Familial Hypercholesterolemia - Feb 14th, 2023 11:30 am
2 High-Risk, High-Reward Stock Bets Cathie Wood Is Taking Into 2023 - Feb 6th, 2023 2:35 pm
Being Cautious On Regulatory/Commercial Path, This Analyst Initiates Coverage On Verve Therapeutics - Feb 1st, 2023 7:10 pm
7 CRISPR Stocks With the Best Long-Term Potential - Jan 31st, 2023 12:10 am
Verve Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference - Jan 3rd, 2023 9:05 pm
Cathie Wood Is Loading Up On These 12 Stocks - Dec 24th, 2022 11:13 pm
Analyst Beefs Up Beam Therapeutics Price Target, Says 'Reward Is Now Skewed To Upside' - Dec 20th, 2022 6:51 pm